tetano
Editor, Senior Moderator
BMJ Open
. 2025 Sep 23;15(9):e094948.
doi: 10.1136/bmjopen-2024-094948. Antibody development after three mRNA SARS-CoV-2 vaccinations in patients with systemic autoimmune rheumatic disease with and without treatment: an observational cohort study
Elisabeth Simader[SUP] 1 [/SUP], Felix Kartnig[SUP] 2 [/SUP], Selma Tobudic[SUP] 3 [/SUP], Daniel Mrak[SUP] 2 [/SUP], Thomas Deimel[SUP] 2 [/SUP], Thomas Karonitsch[SUP] 2 [/SUP], Helmuth Haslacher[SUP] 4 [/SUP], Thomas Perkmann[SUP] 4 [/SUP], Gregor Mitter[SUP] 2 [/SUP], Stefan Winkler[SUP] 3 [/SUP], Daniel Aletaha[SUP] 2 [/SUP], Stephan Blueml[SUP] 2 [/SUP], Peter Mandl[SUP] 2 [/SUP]
Affiliations
Objectives and design: To further elucidate the effects of rare systemic autoimmune rheumatic diseases (SARD) and their treatment on antibody development after vaccination against SARS-CoV-2, we compared patients with and without immunosuppressive therapy to healthy controls in an observational cohort study.
Participants and setting: We enrolled 52 patients with SARD and 72 healthy subjects in a prospective, observational study at the Medical University of Vienna and measured the humoral response 6 months after two mRNA vaccinations and 2-6 weeks after a third dose.
Results: Patients with vasculitis showed significantly (p=0.02) lower antibody titres 6 months after vaccination (median 247 BAU/mL, IQR [185-437]), as compared with healthy controls (median 514 BAU/mL, [185-437], IQR 323; 928, vasculitis patients: 247, IQR [185; 437], p<0.05). Patients receiving 2-3 immunomodulatory medications showed significantly lower antibody levels. Of note, all patients with SARD, even those without immunomodulatory medication, developed lower antibody levels after the third dose compared with healthy controls (median 22 630, IQR [16 945; 43 200] in HC, 9510 IQR [3866; 14 215] in patients without immunosuppressive treatment (p<0.001), 7780 IQR [2203; 15 645] in patients receiving a single immunomodulatory drug (p<0.0001) and 14 320 IQR [2415; 35 400] in patients receiving combination therapy (p=0.081)).
Conclusions: Patients with SARD displayed lower antibody development after booster vaccination, even if antibody levels after two immunisations were comparable to healthy controls. Our data may be limited due to sample size, but it provides pointers for a more individualised, antibody-titre-oriented approach and earlier booster vaccination in patients with SARD.
Keywords: COVID-19; Chronic Disease; IMMUNOLOGY; Rheumatology.
. 2025 Sep 23;15(9):e094948.
doi: 10.1136/bmjopen-2024-094948. Antibody development after three mRNA SARS-CoV-2 vaccinations in patients with systemic autoimmune rheumatic disease with and without treatment: an observational cohort study
Elisabeth Simader[SUP] 1 [/SUP], Felix Kartnig[SUP] 2 [/SUP], Selma Tobudic[SUP] 3 [/SUP], Daniel Mrak[SUP] 2 [/SUP], Thomas Deimel[SUP] 2 [/SUP], Thomas Karonitsch[SUP] 2 [/SUP], Helmuth Haslacher[SUP] 4 [/SUP], Thomas Perkmann[SUP] 4 [/SUP], Gregor Mitter[SUP] 2 [/SUP], Stefan Winkler[SUP] 3 [/SUP], Daniel Aletaha[SUP] 2 [/SUP], Stephan Blueml[SUP] 2 [/SUP], Peter Mandl[SUP] 2 [/SUP]
Affiliations
- PMID: 40987743
- PMCID: PMC12458837
- DOI: 10.1136/bmjopen-2024-094948
Objectives and design: To further elucidate the effects of rare systemic autoimmune rheumatic diseases (SARD) and their treatment on antibody development after vaccination against SARS-CoV-2, we compared patients with and without immunosuppressive therapy to healthy controls in an observational cohort study.
Participants and setting: We enrolled 52 patients with SARD and 72 healthy subjects in a prospective, observational study at the Medical University of Vienna and measured the humoral response 6 months after two mRNA vaccinations and 2-6 weeks after a third dose.
Results: Patients with vasculitis showed significantly (p=0.02) lower antibody titres 6 months after vaccination (median 247 BAU/mL, IQR [185-437]), as compared with healthy controls (median 514 BAU/mL, [185-437], IQR 323; 928, vasculitis patients: 247, IQR [185; 437], p<0.05). Patients receiving 2-3 immunomodulatory medications showed significantly lower antibody levels. Of note, all patients with SARD, even those without immunomodulatory medication, developed lower antibody levels after the third dose compared with healthy controls (median 22 630, IQR [16 945; 43 200] in HC, 9510 IQR [3866; 14 215] in patients without immunosuppressive treatment (p<0.001), 7780 IQR [2203; 15 645] in patients receiving a single immunomodulatory drug (p<0.0001) and 14 320 IQR [2415; 35 400] in patients receiving combination therapy (p=0.081)).
Conclusions: Patients with SARD displayed lower antibody development after booster vaccination, even if antibody levels after two immunisations were comparable to healthy controls. Our data may be limited due to sample size, but it provides pointers for a more individualised, antibody-titre-oriented approach and earlier booster vaccination in patients with SARD.
Keywords: COVID-19; Chronic Disease; IMMUNOLOGY; Rheumatology.